Physician profile
Deanna Derusso
NPI 1962463448
$3,670.63
in general payments reported to CMS, 2019-2025
25 companies · $595 in 2025
The $595 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $414 · 2021: $677 · 2022: $469 · 2023: $490 · 2024: $520 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,620.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $379.52 | 2019-2025 | Synthroid, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $295.67 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $254.16 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Bausch Health US, LLC | $221.87 | 2021-2025 | Aplenzin, Wellbutrin |
| Pfizer INC. | $143.52 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.55 | 2023-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $98.24 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $97.93 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $46.76 | 2020-2024 | Trelegy Ellipta |
| Endo Pharmaceuticals INC. | $45.32 | 2021 | |
| Antares Pharma, INC. | $39.14 | 2019-2020 | |
| Allergan, INC. | $35.51 | 2019 | |
| Nestle Healthcare Nutrition INC. | $30.84 | 2020-2023 | |
| Amneal Pharmaceuticals LLC | $27.97 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $26.37 | 2025 | |
| Bardy Diagnostics, INC. | $25.00 | 2022 | |
| Exact Sciences Corporation | $24.92 | 2025 | The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $23.05 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.66 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.43 | 2019 | |
| Merck Sharp & Dohme LLC | $19.66 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Medtronic, INC. | $18.82 | 2022 | |
| Avion Pharmaceuticals | $16.81 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.64 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Derusso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.